Diana Brainard, M.D, CEO 

Oct. 12 | 2:30pm | UBC Ballroom 

Waltham, MA 


In-person Presentation 

AlloVir is a late clinical-stage cell therapy company focused on restoring natural immunity against life-threatening viral diseases in immunocompromised patients. The company’s innovative, proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells (VSTs) for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single therapy. The company is advancing multiple mid- and late-stage clinical trials across its portfolio. AlloVir’s lead product, Posoleucel, is a multi-VST therapy targeting six viral pathogens: adenovirus, BK virus, cytomegalovirus, Epstein-Barr virus, human herpesvirus-6, and JC virus. Posoleucel is in Phase III development for three distinct indications and has received regulatory designations including FDA’s Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation (ODD), and EMA’s Priority Medicines (PRIME) and Orphan Medicinal Product (OMP). 

By using this website you agree to accept our Privacy Policy and Terms & Conditions